Ketamine for Veterans With Parkinson’s Disease (KPD)

Randomised, triple-masked, active placebo-controlled, single-dose trial comparing IV ketamine 0.5 mg/kg versus remimazolam 0.25 mg/kg in 80 Veterans with Parkinson's disease and moderate-to-severe depression; primary clinical outcome is change in MADRS at 24 hours.

Mechanistic measures include non-invasive neurophysiological assays of LTP-like plasticity and blood cytokine panels to assess ketamine's effects on neuroplasticity and inflammation; safety, tolerability, and adverse events will also be recorded.